AUA 2021: State-of-the-art Lecture: First and Second Line Therapy in Advanced and Metastatic Bladder Cancer: A Changing Paradigm

AUA 2021 First and Second Line Therapy in Advanced and Metastatic Bladder Cancer, metastatic urothelial cancer, MVAC chemotherapy, checkpoint immunotherapy, platinum-refractory advanced UC, Keynote-045 study, IMvigor130 trial, DANUBE trial, KEYNOTE-361 trial.

Related Keywords

United States ,New York ,American ,Thenappan Thenu Chandrasekar ,Morales Barrera ,Homet Moreno ,Cora Sternberg ,Twitter ,American Urologic Association ,Sidney Kimmel Cancer Center ,Study Group ,American Urological Association ,Thomas Jefferson University ,Line Setting ,Platinum Refractory ,Platinum Ineligible ,Sacituzumab Govitecan ,Growth Factor ,Weill Cornell Medicine ,New York Presbyterian ,Urologic Oncologist ,Assistant Professor ,Urological Association ,Annual Meeting ,Double Blind Phase ,Patients With Metastatic Urothelial ,